Company news
Aptahem Ab (NGM:APTA) news
Aptahem Ab news releases on 6ix. Latest, Aug 25, 2026: Aptahem: Aptahem enters commercial partnership agreement with Jarlen Capital for outlicensing
Press releases & updates
Aptahem: Aptahem enters commercial partnership agreement with Jarlen Capital for outlicensing
August 25, 2026
Aptahem enters commercial partnership agreement with Jarlen Capital for outlicensing
August 25, 2026
Aptahem: Aptahem Improves Quality and Manufacturing Efficiency in a New Apta-1 Test Batch
June 17, 2026
Aptahem Improves Quality and Manufacturing Efficiency in a New Apta-1 Test Batch
June 17, 2026
Aptahem: Aptahem to Participate at IOPC 2026 in Athens
June 5, 2026
Aptahem receives patent protection in China for patent family 2
December 5, 2025
Aptahem : webinar ”Strategic Direction and Planned US Listing” now available
October 30, 2025
Aptahem: Aptahem’s webinar "Strategic Direction and Planned US Listing" now available
October 30, 2025
Aptahem: Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing
October 22, 2025
Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing
October 22, 2025
Aptahem : CEO’s thoughts on AMR and sepsis
October 15, 2025
Aptahem : Mikael Lindstam shares his reflections from BIO Japan
October 13, 2025
Aptahem: Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue
September 25, 2025
Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue
September 25, 2025
Aptahem: Aptahem receives Notice of Allowance in China for patent family 2
September 23, 2025
Aptahem receives Notice of Allowance in China for patent family 2
September 23, 2025
Aptahem: Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation
September 19, 2025
Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation
September 19, 2025
Aptahem : Aptahems VD interjuad av Mangold Insight
September 16, 2025
Aptahem: Aptahem is applying to the FDA's CNPV pilot program for accelerated drug review
August 27, 2025
Aptahem is applying to the FDA's CNPV pilot program for accelerated drug review
August 27, 2025